Safety and Efficacy of Sustained Erythropoietin Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Medgenics Medical Israel Ltd.
ClinicalTrials.gov Identifier:
NCT00542568
First received: October 10, 2007
Last updated: April 16, 2014
Last verified: April 2014
  Purpose

The purposes of this study are to assess safety, efficacy, and subject satisfaction of EPODURE Biopump (an autologous dermal biopump capable of sustained secretion of therapeutic EPO in the body, using a small tissue explant from the patient's own skin) treatment in Chronic Kidney Disease (CKD) patients over a period of up to six (6) months.


Condition Intervention Phase
Anemia
Biological: EPODURE (dermal Biopump for erythropoietin)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients Using EPODURE Biopump

Resource links provided by NLM:


Further study details as provided by Medgenics Medical Israel Ltd.:

Primary Outcome Measures:
  • Safety Endpoints: adverse events; safety laboratory values; immune response by determination of anti-EPO antibodies; dermal safety outcomes [ Time Frame: 6 weeks and 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Elevation of serum EPO levels at least 10 mU/ml above baseline for duration of at least six (6) weeks following implantation [ Time Frame: 6 weeks and 4 months ] [ Designated as safety issue: Yes ]

Enrollment: 19
Study Start Date: August 2008
Study Completion Date: January 2013
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cohort 1 (Low Dose group) 18-25 IU/kg/day
Biological: EPODURE (dermal Biopump for erythropoietin)
Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
Experimental: 2
Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
Biological: EPODURE (dermal Biopump for erythropoietin)
Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
Experimental: 3
Cohort 3 (High Dose group): 55-65 IU/kg/day
Biological: EPODURE (dermal Biopump for erythropoietin)
Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump

Detailed Description:

Anemia, is a common complication of chronic kidney disease (CKD) resulting from insufficient production of the hormone erythropoietin by the damaged kidney leading to a decrease in red blood cells production by the bone marrow.

Replacement therapy with recombinant human erythropoietin can effectively correct anemia in patients. However, despite the availability of recombinant human erythropoietin for more than a decade for use in CKD patients, two thirds of patients initiating dialysis have a hematocrit less than 30%, and three fourths have a hemoglobin (Hb) less than 11 g/dL the level recommended by the National Kidney Foundation Kidney Disease Outcome Quality Initiative. Treatment with recombinant human erythropoietin typically involves subcutaneous (SC) administration at regular intervals followed by frequent laboratory tests to monitor hemoglobin concentration. There is a need to provide an significantly improved care in this area using a sustained therapy approach.

EPODURE, is an autologous dermal biopump capable of sustained secretion of therapeutic EPO in the body, using a small tissue explant from the patient's own skin. The EPODURE biopump is harvested directly from the patient's dermis under local anesthetic. EPODURE Biopumps, produced by ex vivo transduction of MOs with Helper Dependent Adenoviral EPO vectors (HDAd-EPO), expresses and secretes EPO. The EPODURE Biopump is subsequently implanted subcutaneously back to the patient in order to provide continuous delivery of a known amount of EPO.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult male or female subjects between 18 to 75 years of age at the time of screening visit.
  2. Subject with Anemia of Chronic Renal Failure CKD stage 3-4. estimated GFR of 15-60 ml/min with Female: Hb < 10 g%, Male: Hb < 11 g%.
  3. Chronic renal failure subjects who are EPO naïve or have been off EPO or similar Erythropoietic drugs for more than four (4) weeks.
  4. Subjects who are clinically stable.
  5. Adequate iron stores (transferrin saturation ≥ 20.0% and ferritin ≥100 ng/ml).
  6. Subjects who receive anti-coagulation treatment may be enrolled provided anti-coagulation treatment can be discontinued two weeks prior to the harvesting visit. INR level must be within normal range (0.9 - 1.5).

Signed written informed consent to participate in the study by subject

Exclusion Criteria:

  1. Uncontrolled hypertension (defined as diastolic blood pressure > 110 mmHg or systolic blood pressure > 180 mmHg during screening).
  2. Congestive heart failure (New York Heart Association functional class III or IV).
  3. Grand mal seizures within 2 years of the screening visit.
  4. Clinical evidence of severe hyperparathyroidism as defined by PTH levels of > 10 times the upper normal limits.
  5. Major surgery within 12 weeks of the screening visit.
  6. Systemic hematologic diseases (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia).
  7. Current systemic infection, active inflammatory disease, or malignancy under treatment.
  8. Known positivity for HIV antibody.
  9. Subjects known to have tested positive at any time in the past for antibodies to erythropoietic proteins.
  10. Subject has history of malignancy within the past 2 years prior to the screening visit, with the exception of basal cell carcinoma.
  11. Subjects with other concurrent severe and/or uncontrolled medical condition which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, uncompensated cirrhosis, active upper GI tract ulceration).
  12. Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s).
  13. Psychiatric, addictive, or any other disorder that compromises ability to give truly informed consent for participation in this study.
  14. Female subjects of child-bearing potential and not having undergone permanent sterilization procedures.
  15. Pregnant and lactating female subjects.
  16. Chronic alcoholic or drug abuse subjects.
  17. Steroid or other immunosuppressive treatment.
  18. Subjects unwilling or unable to comply with the study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00542568

Locations
Israel
Hadassah Medical Organization
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Medgenics Medical Israel Ltd.
Investigators
Principal Investigator: Prof. Eithan Galun, M.D Hadassah Medical Center
Principal Investigator: Doron Schwartz, MD Tel-Aviv Sourasky Medical Center
  More Information

No publications provided

Responsible Party: Medgenics Medical Israel Ltd.
ClinicalTrials.gov Identifier: NCT00542568     History of Changes
Other Study ID Numbers: MG-001-02
Study First Received: October 10, 2007
Last Updated: April 16, 2014
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Anemia
Renal Insufficiency, Chronic
Hematologic Diseases
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Epoetin alfa
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 26, 2014